Vaccination with human papillomavirus type 16 E7 peptide with CpG oligonucleotides for prevention of tumor growth in mice

Archives of Otolaryngology - Head and Neck Surgery

Volumn 132, Issue 3, 2006, Pages 327-332

  Gendron, Kristin B ^a   Rodriguez, Alex ^a   Sewell, Duane A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Biomedical Research Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; PROTEIN E7; TETRAMER; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HUMAN PAPILLOMAVIRUS TYPE 16; IN VIVO STUDY; MOUSE; NONHUMAN; SURVIVAL; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; HUMAN PAPILLOMAVIRUS 16; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; SPLEEN; VACCINATION;

EID: 33645223095     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.132.3.327     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
3. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001;344:1125-1131.
4. Mineta H, Ogino T, Amano HM, et al. Human papilloma virus (HPV) type 16 and 18 detected in head and neck squamous cell carcinoma. Anticancer Res. 1998;18(6B):4765-4768.
5. Ha PK, Califano JA. The role of human papillomavirus in oral carcinogenesis. Crit Rev Oral Biol Med. 2004;15:188-196.
6. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709-720.
7. Stoler MH. Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol. 2000;19:16-28.
8. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-1651.
9. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21-26.
10. Sewell DA, Douven D, Pan ZK, et al. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch Otolaryngol Head Neck Surg. 2004;130:92-97.
11. Gunn GR, Zubair A, Peters C, et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol. 2001;167:6471-6479.
12. Cirillo JD, Stover CK, Bloom BR, et al. Bacterial vaccine vectors and bacillus Calmette-Guerin. Clin Infect Dis. 1995;20:1001-1009.
13. Sewell DA, Shahabi V, Gunn GR III, et al. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res. 2004;64:8821-8825.
14. Klinman DM, Currie D, Gursel I, et al. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev. 2004;199:201-216.
15. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol. 1999;73:329-368.
16. Krieg AM, Hartmann G, Yi AK. Mechanism of action of CpG DNA. Curr Top Microbiol Immunol. 2000;247:1-21.
17. Kim TY, Myoung HJ, Kim JH, et al. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res. 2002;62:7234-7240.
18. Welters MJ, Filippov DV, van den Eeden SJ, et al. Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. Vaccine. 2004;23:305-311.
19. Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol. 2002;169:350-358.
20. Kim TG, Kim CH, Won EH, et al. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Immunology. 2004;112:117-125.
21. Tussey L, Speller S, Gallimore A, et al. Functionally distinct CD8+ memory T cell subsets in persistent EBV infection are differentiated by migratory receptor expression. Eur J Immunol. 2000;30:1823-1829.
22. Pietersz GA, Apostolopoulos V, McKenzie IF. Generation of cellular immune responses to antigenic tumor peptides. Cell Mol Life Sci. 2000;57:290-310.
23. Toes RE, van der Voort EI, Schoenberger SP, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol. 1998;160:4449-4456.
24. Lienard D, Rimoldi D, Marchand M, et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun. 2004;4:4.
25. van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer. 1999;35:946-952.
26. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cellmediated suppression by dendritic cells. Science. 2003;299:1033-1036.